SMITHKLINE-BEECHAM TUMS SALES REACH $138.9 MIL.
This article was originally published in The Tan Sheet
SMITHKLINE-BEECHAM TUMS SALES REACH $138.9 MIL. in food and drug stores combined for the 12 months ended June 30, according to Information Resources' subsidiary Towne-Oller. Sales for the antacid leader through June were up 15% compared to a year ago, the data show. Tums held a 17.7% share of the broad antacid market tracked by Towne-Oller, which includes products with additional indications outside the antacid area such as Procter & Gamble's Pepto-Bismol and McNeil's Lactaid for lactose intolerance.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC